Your browser is no longer supported. Please, upgrade your browser.
Settings
PHAR [NASD]
Pharming Group N.V.
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand63.88M Perf Week2.84%
Market Cap843.25M Forward P/E- EPS next Y- Insider Trans- Shs Float62.56M Perf Month-1.49%
Income- PEG- EPS next Q- Inst Own- Short Float0.00% Perf Quarter-5.92%
Sales185.69M P/S4.54 EPS this Y- Inst Trans- Short Ratio0.19 Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range12.24 - 21.99 Perf YTD-13.13%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-39.97% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low7.88% ATR0.37
Employees262 Current Ratio- Sales Q/Q11.60% Oper. Margin- RSI (14)52.63 Volatility1.98% 1.93%
OptionableNo Debt/Eq- EPS Q/Q-38.70% Profit Margin- Rel Volume1.02 Prev Close12.60
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume5.55K Price13.20
Recom- SMA201.49% SMA500.03% SMA200-4.17% Volume5,633 Change4.78%
Apr-22-21 01:00AM  
Apr-07-21 04:00PM  
Apr-06-21 05:30PM  
Mar-23-21 02:00AM  
Mar-16-21 08:10AM  
Mar-11-21 01:00AM  
Mar-04-21 01:00AM  
Mar-02-21 01:00AM  
Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has development collaboration and license agreement with Novartis. Pharming Group N.V. is headquartered in Leiden, the Netherlands.